• 1
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 2
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 134653.
  • 3
    Bell MJ, Bombardier C, Tugwell P. Measurement of functional status, quality of life, and utility in rheumatoid arthritis. Arthritis Rheum 1990; 33: 591601.
  • 4
    Tugwell P, Bombardier C, Gent M. Low dose cyclosporine versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 100516.
  • 5
    The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995; 98: 15668.
  • 6
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 7
    Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38: 156880.
  • 8
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 9
    Bombardier C, Rabat J, and the Auranofin Cooperating Group. A comparison of health related quality of life measures for rheumatoid arthritis research. Control Clin Trials 1991; 12: 243S56S.
  • 10
    Ware JE, Sherbourne CD. The MOS SF-36 item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 11
    Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997; 50: 7993.
  • 12
    Ruta DA, Hurst JP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 42536.
  • 13
    Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Suarez-Almazor M, et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 21721.
  • 14
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon GW, et al, on behalf of the Leflunomide RA Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 15
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 18708.
  • 16
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health status survey manual. Boston: The Health Institute, New England Medical Center, 1993.
  • 17
    Tomlin GS, Holm MB, Rogers JC, Kwoh CK. Comparison of standard and alternative Health Assessment Questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 152430.
  • 18
    Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41: 156470.